Gene · 28882
Papers3,857
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 3,857
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The Machinability of Different Albromet W130 Plates Thicknesses by WEDM to the Required Surface Roughness Value. | Materials (Basel) | 2024 | 39597344 | PubTator, text mining | PubMed |
| Short and long-term blockades of adenosine 2A, 5-HT2A, and 5-HT7 receptors induce apoptosis, reduce proliferation, and show differential effects on miR-27b-3p expression in neuroblastoma cell lines. | Neuroscience | 2024 | 39547336 | PubTator, text mining | PubMed |
| Insight into adenosine pathway in psoriasis: Elucidating its role and the potential therapeutical applications. | Life Sci | 2024 | 39307180 | PubTator, text mining | PubMed |
| Control of Dopamine Signal in High-Order Receptor Complex on Striatal Astrocytes. | Int J Mol Sci | 2024 | 39201299 | PubTator, text mining | PubMed |
| Dual A2A/A2B Adenosine Receptor Antagonist M1069 Counteracts Immunosuppressive Mechanisms of Adenosine and Reduces Tumor Growth In Vivo. | Mol Cancer Ther | 2024 | 39162025 | PubTator, text mining | PubMed |
| Current Understanding of the Role of Adenosine Receptors in Cancer. | Molecules | 2024 | 39124905 | PubTator, text mining | PubMed |
| The prebiotic emergence of biological evolution. | R Soc Open Sci | 2024 | 39050718 | PubTator, text mining | PubMed |
| Unlocking the adenosine receptor mechanism of the tumour immune microenvironment. | Front Immunol | 2024 | 38994361 | PubTator, text mining | PubMed |
| Sustained Alleviation of Autoimmunity by Activating α2B-adrenergic Receptors. | J Immunol | 2024 | 38940628 | PubTator, text mining | PubMed |
| 2-Aryladenine Derivatives as a Potent Scaffold for Adenosine Receptor Antagonists: The 6-Morpholino Derivatives. | Molecules | 2024 | 38893418 | PubTator, text mining | PubMed |
| Effect of Xanthohumol, a Bioactive Natural Compound from Hops, on Adenosine Pathway in Rat C6 Glioma and Human SH-SY5Y Neuroblastoma Cell Lines. | Nutrients | 2024 | 38892725 | PubTator, text mining | PubMed |
| In Vitro Activation of Human Adrenergic Receptors and Trace Amine-Associated Receptor 1 by Phenethylamine Analogues Present in Food Supplements. | Nutrients | 2024 | 38892500 | PubTator, text mining | PubMed |
| Adenosine and Its Receptors in the Pathogenesis and Treatment of Inflammatory Skin Diseases. | Int J Mol Sci | 2024 | 38891997 | PubTator, text mining | PubMed |
| Targeting Adenosine A2b Receptor Promotes Penile Rehabilitation of Refractory Erectile Dysfunction. | Adv Sci (Weinh) | 2024 | 38874549 | PubTator, text mining | PubMed |
| Structural Insights into Partial Activation of the Prototypic G Protein-Coupled Adenosine A2A Receptor. | ACS Pharmacol Transl Sci | 2024 | 38751633 | PubTator, text mining | PubMed |
| Resveratrol prevents the release of neutrophil extracellular traps (NETs) by controlling hydrogen peroxide levels and nuclear elastase migration. | Sci Rep | 2024 | 38643283 | PubTator, text mining | PubMed |
| Targeting the adenosine signaling pathway in macrophages for cancer immunotherapy. | Hum Immunol | 2024 | 38521664 | PubTator, text mining | PubMed |
| Adrenergic receptor system as a pharmacological target in the treatment of epilepsy (Review). | Med Int (Lond) | 2024 | 38476984 | PubTator, text mining | PubMed |
| Role of deubiquitinase JOSD2 in the pathogenesis of esophageal squamous cell carcinoma. | World J Gastroenterol | 2024 | 38463028 | PubTator, text mining | PubMed |
| Exploring Biginelli-based scaffolds as A2B adenosine receptor antagonists: Unveiling novel structure-activity relationship trends, lead compounds, and potent colorectal anticancer agents. | Biomed Pharmacother | 2024 | 38442670 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/28882/papers?page=5